Wound News and Research

RSS

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Amputation prevention tips for diabetic patients

While "One Foot, Two Foot, Red Foot, Blue Foot" may be the opening line of a humorous children's book by Dr. Seuss, foot complications are no laughing matter to the 20 million Americans with diabetes. According to the American Orthopaedic Foot & Ankle Society (AOFAS), ulceration, infection, and gangrene are the most common foot and ankle problems of the diabetic patient.

21 Oct 2009

MediWound reports positive results from phase III Debrase trial for treating burns

Teva Pharmaceutical Industries Ltd. announced today that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase®, an enzymatic debriding agent for burns.

21 Oct 2009

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

19 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

PEAK Surgical's PRECISE clinical study results presented at the 95th ACS Congress

PEAK Surgical, Inc. today announced results from the first of its PRECISE Clinical Studies (Pulsed Plasma Radiofrequency Energy to ReduCe Thermal Injury and Improve Surgical HEaling) demonstrating that its PEAK PlasmaBlade® tissue dissection device is associated with significant improvements in post-operative wound drainage, narcotic consumption, thermal injury, wound strength and return to normal diet volume compared with the standard of care.

15 Oct 2009

MDEA program is accepting entries for its 2010 competition

The Medical Design Excellence Awards (MDEA) program is accepting entries for its 2010 competition from companies and individuals worldwide involved in the design, engineering, manufacture, or distribution of finished medical devices or packaging products.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

NIBIB awards $1M grant to develop a rapid test for sepsis-related pathogens

Smiths Detection today announces the award of a $1m, two-year grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to develop a rapid test for eight micro-organisms that commonly cause burn/wound infections leading to septicemia (blood-poisoning).

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Covidien launches V-Loc absorbable wound closure device

Covidien, a leading global provider of healthcare products, today announced the global rollout of the V-Loc™ absorbable wound closure device, the first surgical device of its kind to feature unidirectional barbed technology that enables surgeons to close dermal wounds quickly and securely without tying knots.

13 Oct 2009

Systagenix Wound Management forms new global Medical Advisory Board

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

13 Oct 2009

Simple wound dressings versus antimicrobial dressings

The UK National Health Service could save millions of pounds a year by routinely using inexpensive dressings to treat venous leg ulcers, after a study published in the October issue of BJS showed that they are just as effective as expensive silver dressings in the majority of cases.

13 Oct 2009

Kinetic Concepts to showcase its ABThera OA NPT System at the American College of Surgeons Congress

Kinetic Concepts, Inc. will feature ABThera™ Open Abdomen Negative Pressure Therapy System, the latest addition to the KCI Negative Pressure Technology Platform (NPTP), at the American College of Surgeons’ 95th Annual Clinical Congress, Oct. 11-15 in Chicago.

13 Oct 2009

The third annual AdvaMed 2009: The MedTech Conference commences today

Leaders of the medical technology industry convene today through the 14th at the Walter E. Washington Convention Center for the third annual AdvaMed 2009: The MedTech Conference.

13 Oct 2009

VirtualHealth Technologies, Wound Care Innovations enter licensing agreement to use Cifra healthcare platform

VirtualHealth Technologies, Inc., a provider of secure technology for electronic health records and connectivity for web-based healthcare solutions, announced today that its subsidiary Secure eHealth has entered into an agreement with Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies Inc., to use its Cifra secure healthcare platform.

12 Oct 2009

Cifra healthcare platform from Wound Management Technologies

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations, LLC has launched the Cifra(TM) healthcare platform to securely exchange and store information for ongoing evidence based case studies on its patented collagen CellerateRx® products in managing all types of wound care.

12 Oct 2009

Researchers find how KEAP1 tumor suppressor works

A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.

12 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009